Latest & greatest articles for methocarbamol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methocarbamol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methocarbamol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methocarbamol

1. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain

A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain In US emergency departments (EDs), patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxen+placebo versus naproxen+orphenadrine or naproxen+methocarbamol.This was a randomized, double-blind, comparative effectiveness trial (...) conducted in 2 urban EDs. Patients presenting with acute, nontraumatic, nonradicular low back pain were enrolled. The primary outcome was improvement on the Roland-Morris Disability Questionnaire (RMDQ) between ED discharge and 1 week later. All patients were given 14 tablets of naproxen 500 mg, to be used twice a day, as needed for low back pain. Additionally, patients were randomized to receive a 1-week supply of orphenadrine 100 mg, to be used twice a day as needed, methocarbamol 750 mg, to be used

2018 EvidenceUpdates

2. Methocarbamol

Methocarbamol Top results for methocarbamol - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for methocarbamol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. (PubMed)

A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. In US emergency departments (EDs), patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxen+placebo versus naproxen+orphenadrine or naproxen+methocarbamol.This was a randomized, double-blind, comparative effectiveness (...) trial conducted in 2 urban EDs. Patients presenting with acute, nontraumatic, nonradicular low back pain were enrolled. The primary outcome was improvement on the Roland-Morris Disability Questionnaire (RMDQ) between ED discharge and 1 week later. All patients were given 14 tablets of naproxen 500 mg, to be used twice a day, as needed for low back pain. Additionally, patients were randomized to receive a 1-week supply of orphenadrine 100 mg, to be used twice a day as needed, methocarbamol 750 mg

2017 Annals of Emergency Medicine

4. Orphenadrine and Methocarbamol for LBP

Orphenadrine and Methocarbamol for LBP Orphenadrine and Methocarbamol for LBP - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Orphenadrine and Methocarbamol for LBP The safety and scientific validity (...) Description Go to Brief Summary: Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone Condition or disease Intervention/treatment Phase Low Back Pain Drug: Orphenadrine Drug: Methocarbamol Drug: Naproxen Drug: Placebo Phase 4 Detailed Description: Patients

2016 Clinical Trials

5. Some studies on peripheral actions of mephenesin, methocarbamol and diazepam (PubMed)

Some studies on peripheral actions of mephenesin, methocarbamol and diazepam 1. Mephenesin, methocarbamol and diazepam abolished polysynaptic reflex contractions of the cat tibialis anterior muscle elicited by stimulation of the homolateral femoral nerve.2. Mephenesin and methocarbamol caused a prolongation of the mean refractory period of directly or indirectly stimulated skeletal muscle. These effects were due to a direct action on the muscle fibres. There was no effect on responses to single (...) stimuli.3. The increase in refractory period produced by mephenesin was greater in indirectly than in directly stimulated rat diaphragms. Experiments using the isolated phrenic nerve suggest that this difference is due to the local anaesthetic action of mephenesin.4. In the indirectly stimulated cat tibialis anterior muscle high frequency stimulation resulted in a non-maintained tetanus in the presence of mephenesin and methocarbamol.5. Diazepam was without peripheral effects on the responses

Full Text available with Trip Pro

1968 British journal of pharmacology

6. [Methocarbamol in acute low back pain. A randomized double-blind controlled study]. (PubMed)

[Methocarbamol in acute low back pain. A randomized double-blind controlled study]. Muscle relaxants are widely used to treat low back pain (LBP), one of the most frequent health problems in industrialized countries. For this indication, the European Medicines Agency (EMA) recently had imposed restrictions for some muscle relaxants, anti-inflammatories and analgesics; Tetrazepam even had to be withdrawn from the market. Therefore methocarbamol remains the only approved muscle relaxant (...) . Methocarbamol is well-established for the treatment of LBP associated with myofascial components, although more recent clinical studies have not been published. Therefore this publication summarizes and revaluates post-hoc data of an efficiency study of methocarbamol, that was performed in 2002, but had not been published yet.This was a randomized, placebo controlled multi-centre study. Inclusion criteria were acute low back pain for at least 24 h associated with spasms in the pelvic/lumbar region

2015 MMW Fortschritte der Medizin

7. A double-blind trial of methocarbamol versus placebo in painful muscle spasm. (PubMed)

A double-blind trial of methocarbamol versus placebo in painful muscle spasm. A double-blind trial of methocarbamol versus placebo was carried out in 59 matched pairs of patients suffering from painful muscle spasm. Methocarbamol (1500 mg. q.d.s.) was found to be effective in approximately 60% of patients compared with 30% of patients receiving placebo (p less than 0.01). Side-effects were of almost equal incidence in the two groups.

1975 Current medical research and opinion

8. 50 Years Ago in CORR: A Clinical Study of 46 Males With Low-Back Disorders Treated with Methocarbamol Andres Grisolia MD and J.E.M. Thomson CORR 1959;13:299–304 (PubMed)

50 Years Ago in CORR: A Clinical Study of 46 Males With Low-Back Disorders Treated with Methocarbamol Andres Grisolia MD and J.E.M. Thomson CORR 1959;13:299–304 19636647 2009 10 15 2018 11 13 1528-1132 467 10 2009 Oct Clinical orthopaedics and related research Clin. Orthop. Relat. Res. 50 Years Ago in CORR: A clinical study of 46 males with low-back disorders treated with Methocarbamol. Andres Grisolia MD and J.E.M. Thomson CORR 1959;13:299-304. 2752-4 10.1007/s11999-009-1002-8 Brand Richard (...) A RA Clinical Orthopaedics and Related Research, Philadelphia, PA, USA. dick.brand@clinorthop.org eng Historical Article Journal Article 2009 07 28 United States Clin Orthop Relat Res 0075674 0009-921X 0 Muscle Relaxants, Central 0 Placebos 125OD7737X Methocarbamol AIM IM Controlled Clinical Trials as Topic history History, 18th Century History, 19th Century History, 20th Century Humans Low Back Pain drug therapy history Male Methocarbamol history therapeutic use Muscle Relaxants, Central history

Full Text available with Trip Pro

2009 Clinical Orthopaedics and Related Research

9. [Motor test in cerebral palsy treated with methocarbamol]. (PubMed)

[Motor test in cerebral palsy treated with methocarbamol]. 5076834 1972 12 04 2013 11 21 0023-7205 69 44 1972 Oct 25 Lakartidningen Lakartidningen [Motor test in cerebral palsy treated with methocarbamol]. 5074-6 Bjerre I I Blennow G G swe Clinical Trial Controlled Clinical Trial Journal Article Randomized Controlled Trial Motoriskt test vid cerebral pares behandlad med metokarbamol. Sweden Lakartidningen 0027707 0023-7205 0 Placebos 125OD7737X Methocarbamol IM Administration, Oral Adolescent (...) Cerebral Palsy drug therapy physiopathology Child Child, Preschool Extremities physiopathology Female Follow-Up Studies Gait Humans Locomotion Male Methocarbamol administration & dosage therapeutic use Motor Activity drug effects Placebos Posture Time Factors 1972 10 25 1972 10 25 0 1 1972 10 25 0 0 ppublish 5076834

1972 Lakartidningen

10. A controlled study of methocarbamol (Robaxin) in acute painful musculoskeletal conditions. (PubMed)

A controlled study of methocarbamol (Robaxin) in acute painful musculoskeletal conditions. 808374 1975 11 22 2013 11 21 0011-393X 17 6 1975 Jun Current therapeutic research, clinical and experimental Curr Ther Res Clin Exp A controlled study of methocarbamol (Robaxin) in acute painful musculoskeletal conditions. 525-30 Tisdale S A SA Jr Ervin D K DK eng Clinical Trial Journal Article Randomized Controlled Trial United States Curr Ther Res Clin Exp 0372621 0011-393X 0 Placebos 125OD7737X (...) Methocarbamol IM Adult Clinical Trials as Topic Female Humans Male Methocarbamol adverse effects therapeutic use Muscular Diseases drug therapy Pain drug therapy Placebos Spasm drug therapy Time Factors 1975 6 1 2001 3 28 10 1 1975 6 1 0 0 ppublish 808374

1975 Current therapeutic research, clinical and experimental

11. [Methocarbamol: central building block in multimodal therapy]. (PubMed)

[Methocarbamol: central building block in multimodal therapy]. 27333626 2016 08 04 2016 06 22 1438-3276 158 9 2016 May 12 MMW Fortschritte der Medizin MMW Fortschr Med [Methocarbamol: central building block in multimodal therapy]. 72-3 ger Journal Article Randomized Controlled Trial Methocarbamol: Zentraler Baustein der multimodalen Therapie. Germany MMW Fortschr Med 100893959 1438-3276 125OD7737X Methocarbamol IM Back Pain drug therapy Combined Modality Therapy General Practice Humans (...) Methocarbamol therapeutic use Myofascial Pain Syndromes drug therapy 2016 6 24 6 0 2016 6 24 6 0 2016 8 5 6 0 ppublish 27333626

2016 MMW Fortschritte der Medizin

12. Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients

Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Methocarbamol in Treatment (...) Information provided by (Responsible Party): Sherief Abd-Elsalam, Tanta University Study Details Study Description Go to Brief Summary: Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The mechanism of action of methocarbamol is currently unknown, but may involve the inhibition of carbonic anhydrase. Methocarbamol has a high therapeutic index, i.e. a wide range of safe

2015 Clinical Trials

13. Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. (PubMed)

Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. Muscle cramps occur in 29-88% of patients with liver cirrhosis. They adversely affect quality of life. This study aimed to evaluate the efficacy and safety of methocarbamol as a novel therapy in controlling muscle cramps in cirrhotic patients.This study was carried on 100 patients with liver cirrhosis in addition to chronic hepatitis C who presented with frequent muscle cramps (≥three (...) cramps per week). Half of these patients received methocarbamol and the other half received placebo. This was done through equal randomization. Questionnaires on muscle cramp were answered. Patients were evaluated before, after 1 month of treatment, and 2 weeks after washout of treatment in terms of severity, duration, and frequency of cramps. Liver, renal functions, and electrolytes were analyzed. Also, any side effect was detected.Patients who were treated with methocarbamol showed a significant

2018 European journal of gastroenterology & hepatology

14. USE OF METHOCARBAMOL IN ORTHOPEDICS (PubMed)

USE OF METHOCARBAMOL IN ORTHOPEDICS A new skeletal muscle relaxant, methocarbamol, was used in the treatment of 38 patients with a variety of severe neurological disorders and skeletal muscle spasm states.Eighty-two per cent of the patients studied obtained a beneficial result ranging from excellent to fair. Mild side effects such as drowsiness were observed in five patients, mild weakness in three patients and excessive perspiration in one. In two of the five patients who complained

Full Text available with Trip Pro

1959 California Medicine

15. Mephenesin, methocarbamol, chlordiazepoxide and diazepam: Actions on spinal reflexes and ventral root potentials (PubMed)

Mephenesin, methocarbamol, chlordiazepoxide and diazepam: Actions on spinal reflexes and ventral root potentials 1. Dose levels of mephenesin, methocarbamol, chlordiazepoxide and diazepam which abolished polysynaptic reflex contractions had no effect on monosynaptic knee-jerk reflexes in chloralose anaesthetized cats.2. Ventral root potentials were recorded following stimulation of the corresponding dorsal root (L7 or S1), and the areas of the mono- and polysynaptic components were measured (...) by planimetry.3. Dose levels of the drugs which abolished polysynaptic reflex contractions reduced the areas of the polysynaptic component of the ventral root potentials by about 50%. Mephenesin and methocarbamol reduced the area of the monosynaptic component to a similar extent. Chlordiazepoxide was less potent in this respect while diazepam was without effect at this dose level.4. Linear regression lines were calculated for the reduction in the mono- and polysynaptic components of ventral root potentials

Full Text available with Trip Pro

1970 British journal of pharmacology

16. The role of methocarbamol and intercostal nerve blocks for pain management in breast augmentation. (PubMed)

The role of methocarbamol and intercostal nerve blocks for pain management in breast augmentation. Breast augmentation is one of the most common plastic surgery procedures performed in the United States. The optimal approach to postoperative pain management has yet to be determined.The objective of this study was to investigate the efficacy of intercostal nerve blocks and oral methocarbamol for postoperative pain control.One hundred primary breast augmentation patients were randomized to 1 of 4 (...) treatment groups: (1) methocarbamol given with intercostal blocks, (2) methocarbamol given without intercostal blocks, (3) no methocarbamol given with intercostal blocks, and (4) no methocarbamol or intercostal blocks given. The patients and recovery room nurses were strictly blinded to treatment group assignment.All patients underwent primary augmentation with no other procedures performed. Patients who received intercostal nerve blocks required the same amounts of postoperative narcotics as those who

Full Text available with Trip Pro

2009 Aesthetic surgery journal

17. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. (PubMed)

Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. The effects of orally administered placebo, diphenhydramine, lorazepam, methocarbamol and placebo were studied in volunteers with histories of recreational substance abuse including sedative/hypnotics. Placebo, diphenhydramine (100, 200 and 400 mg), lorazepam (1 and 4 mg) and methocarbamol (2.25 and 9 g) were tested in a randomized, double-blind crossover study using 14 subjects (...) . Psychomotor and cognitive performance and subject- and observer-rated responses were measured daily before and for 5.5 hr after drug administration. The results showed that each of the drugs exhibited a different profile of effects on the test battery. Lorazepam produced significant increases in subjects' ratings of drug effect and liking, increases in measures of sedation and impairment of psychomotor performance. Methocarbamol also produced significant increases in subjects' ratings of drug effect

1992 The Journal of pharmacology and experimental therapeutics

18. Evaluation of the abuse potential of methocarbamol. (PubMed)

Evaluation of the abuse potential of methocarbamol. The subjective and behavioral effects of p.o. administered methocarbamol, lorazepam and placebo were studied in a nonresidential group of adult male volunteers with histories of recreational substance abuse including sedative/hypnotics. In the first phase of the investigation, a dose run-up of methocarbamol (up to 12 g) was conducted in six subjects to determine appropriate doses. In the second phase, a randomized block cross-over study using (...) 14 subjects was conducted. The following drug conditions were tested in the cross-over phase: placebo, lorazepam 1, 2 and 4 mg, and methocarbamol 2.25, 4.5 and 9 g. Drug conditions were tested under double-blind conditions. Psychomotor and cognitive performance measures and subject- and observer-rated behavioral responses were measured daily before dosing and for 5.5 hr after drug administration. The results showed that both lorazepam and methocarbamol produced statistically significant dose

1989 The Journal of pharmacology and experimental therapeutics

19. Bioequivalence study with two different oral formulations of methocarbamol in healthy subjects. A mono-centre, comparative, randomized, open-label, single-dose, 2-way crossover study. (PubMed)

Bioequivalence study with two different oral formulations of methocarbamol in healthy subjects. A mono-centre, comparative, randomized, open-label, single-dose, 2-way crossover study. The objective of this study was to compare the pharmacokinetic profile of a new oral methocarbamol (CAS 532-03-6) formulation (DoloVisano Methocarbamol 750 mg Tabletten) to that of a registered reference product and to demonstrate the bioequivalence of the formulations with respect to rate and extent (...) of methocarbamol exposure.This bioequivalence trial was based on an open-label, single-dose, randomized, two-treatment, two-period crossover design. In each period 32 male or female healthy white volunteers received 2 tablets (2 x 750 mg methocarbamol) of either the test (a) or the reference (b) product after an overnight fasting of at least 12 h. Breakfast was served 4 h after dosing. The two treatment sequences were separated by a wash-out phase of 6 days. Blood samples were drawn prior to the first single

2009 Arzneimittel-Forschung

20. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. (PubMed)

A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. In US emergency departments (EDs), patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxen+placebo versus naproxen+orphenadrine or naproxen+methocarbamol.This was a randomized, double-blind, comparative effectiveness (...) trial conducted in 2 urban EDs. Patients presenting with acute, nontraumatic, nonradicular low back pain were enrolled. The primary outcome was improvement on the Roland-Morris Disability Questionnaire (RMDQ) between ED discharge and 1 week later. All patients were given 14 tablets of naproxen 500 mg, to be used twice a day, as needed for low back pain. Additionally, patients were randomized to receive a 1-week supply of orphenadrine 100 mg, to be used twice a day as needed, methocarbamol 750 mg

2018 Annals of Emergency Medicine